Article Text

Download PDFPDF
Safety of chemotherapy prescription and production software: proposal of specific guidelines to test new versions
  1. Bertrand Pourroy1,
  2. Frederic Benizri2,
  3. Sophie Roubaud3,
  4. Sandra Ruitort4
  1. 1Oncopharma Unit, Pharmacy Department, La Timone University Teaching Hospital, Marseille, France
  2. 2Pharmacy department, Paoli Calmettes Institute Cancer Center, Marseille, France
  3. 3Pharmacy Department, Plein Ciel Clinic, Mougins, France
  4. 4Anticancer Drugs Production Unit Archet II, Pharmacy Departement, Nice University Teaching Hospital, Nice, France
  1. Correspondence to Dr Bertrand Pourroy, Oncopharma Unit, Pharmacy Department, La Timone University Teaching Hospital, 264 rue St Pierre, Marseille 13005, France; bertrand.pourroy{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Medicinal treatment of cancer is critical for patient safety. In fact, anticancer drugs present a narrow therapeutic index with potentially lethal adverse events. Many studies have highlighted the benefit of computerised prescription (CP) in oncology.1 ,2 However, CP may lead to the emergence of new errors defined as e-iatrogenesis that can result in unintended consequences.3 Unfortunately, prescribing software errors are more common than they should be, especially in a high-risk field such as oncology. Such errors, and their putative patient consequences, may occur following software version upgrading. Thus, even if software publishers routinely realise regression tests for …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.